|
1
|
Jonczak E, Grossman J, Alessandrino F,
Seldon Taswell C, Velez-Torres JM and Trent J: Liposarcoma: A
journey into a rare tumor's epidemiology, diagnosis,
pathophysiology, and limitations of current therapies. Cancers
(Basel). 16:38582024. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ducimetière F, Lurkin A, Ranchère-Vince D,
Decouvelaere AV, Péoc'h M, Istier L, Chalabreysse P, Muller C,
Alberti L, Bringuier PP, et al: Incidence of sarcoma histotypes and
molecular subtypes in a prospective epidemiological study with
central pathology review and molecular testing. PLoS One.
6:e202942011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lee ATJ, Thway K, Huang PH and Jones RL:
Clinical and molecular spectrum of liposarcoma. J Clin Oncol.
36:151–159. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Fletcher C, Unni K and Mertens F: World
Health Organization Classification of Tumours. Pathology and
genetics of tumours of soft tissue and bone. 3rd edition. IARC
Press; 2002
|
|
5
|
Zhou XP, Xing JP, Sun LB, Tian SQ, Luo R,
Liu WH, Song XY and Gao SH: Molecular characteristics and systemic
treatment options of liposarcoma: A systematic review. Biomed
Pharmacother. 178:1172042024. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yee EJ, Stewart CL, Clay MR and McCarter
MM: Lipoma and its doppelganger: The atypical lipomatous
tumor/well-differentiated liposarcoma. Surg Clin North Am.
102:637–656. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lu J, Wood D, Ingley E, Koks S and Wong D:
Update on genomic and molecular landscapes of well-differentiated
liposarcoma and dedifferentiated liposarcoma. Mol Biol Rep.
48:3637–3647. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Somaiah N and Tap W: MDM2-p53 in
liposarcoma: The need for targeted therapies with novel mechanisms
of action. Cancer Treat Rev. 122:1026682024. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Thway K: Well-differentiated liposarcoma
and dedifferentiated liposarcoma: An updated review. Semin Diagn
Pathol. 36:112–121. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bouyahya A, El Allam A, Aboulaghras S,
Bakrim S, El Menyiy N, Alshahrani MM, Al Awadh AA, Benali T, Lee
LH, El Omari N, et al: Targeting mTOR as a cancer therapy: Recent
advances in natural bioactive compounds and immunotherapy. Cancers
(Basel). 14:55202022. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Song Z, Lu L, Gao Z, Zhou Q, Wang Z, Sun L
and Zhou Y: Immunotherapy for liposarcoma: Emerging opportunities
and challenges. Future Oncol. 18:3449–3461. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dancsok AR, Setsu N, Gao D, Blay JY,
Thomas D, Maki RG, Nielsen TO and Demicco EG: Expression of
lymphocyte immunoregulatory biomarkers in bone and soft-tissue
sarcomas. Mod Pathol. 32:1772–1785. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kim JR, Moon YJ, Kwon KS, Bae JS, Wagle S,
Kim KM, Park HS, Lee H, Moon WS, Chung MJ, et al: Tumor
infiltrating PD1-positive lymphocytes and the expression of PD-L1
predict poor prognosis of soft tissue sarcomas. PLoS One.
8:e828702013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Smith CA, Martinez SR, Tseng WH, Tamurian
RM, Bold RJ, Borys D and Canter RJ: Predicting survival for
well-differentiated liposarcoma: The importance of tumor location.
J Surg Res. 175:12–17. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Vos M, Koseła-Paterczyk H, Rutkowski P,
van Leenders GJLH, Normantowicz M, Lecyk A, Sleijfer S, Verhoef C
and Grünhagen DJ: Differences in recurrence and survival of
extremity liposarcoma subtypes. Eur J Surg Oncol. 44:1391–1397.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Vos M, Grünhagen DJ, Koseła-Paterczyk H,
Rutkowski P, Sleijfer S and Verhoef C: Natural history of
well-differentiated liposarcoma of the extremity compared to
patients treated with surgery. Surg Oncol. 29:84–89. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Amer KM, Congiusta DV, Thomson JE, Elsamna
S, Chaudhry I, Bozzo A, Amer R, Siracuse B, Ghert M and Beebe KS:
Epidemiology and survival of liposarcoma and its subtypes: A dual
database analysis. J Clin Orthop Trauma. 11 (Suppl 4):S479–S484.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Nascimento AG: Dedifferentiated
liposarcoma. Semin Diagn Pathol. 18:263–266. 2001.PubMed/NCBI
|
|
19
|
Haddox CL and Riedel RF: Recent advances
in the understanding and management of liposarcoma. Fac Rev.
10:12021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mantilla JG, Ricciotti RW, Chen EY, Liu YJ
and Hoch BL: Amplification of DNA damage-inducible transcript 3
(DDIT3) is associated with myxoid liposarcoma-like morphology and
homologous lipoblastic differentiation in dedifferentiated
liposarcoma. Mod Pathol. 32:585–592. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liu H, Wang X, Liu L, Yan B, Qiu F and
Zhou B: Targeting liposarcoma: Unveiling molecular pathways and
therapeutic opportunities. Front Oncol. 14:14840272024. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Casadei L, de Faria FCC, Lopez-Aguiar A,
Pollock RE and Grignol V: Targetable pathways in the treatment of
retroperitoneal liposarcoma. Cancers (Basel). 14:13622022.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hirata M, Asano N, Katayama K, Yoshida A,
Tsuda Y, Sekimizu M, Mitani S, Kobayashi E, Komiyama M, Fujimoto H,
et al: Integrated exome and RNA sequencing of dedifferentiated
liposarcoma. Nat Commun. 10:56832019. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gahvari Z and Parkes A: Dedifferentiated
liposarcoma: Systemic therapy options. Curr Treat Options Oncol.
21:152020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Haddox CL, Hornick JL, Roland CL, Baldini
EH, Keedy VL and Riedel RF: Diagnosis and management of
dedifferentiated liposarcoma: A multidisciplinary position
statement. Cancer Treat Rev. 131:1028462024. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhao J, Du W, Tao X, Li A, Li Y and Zhang
S: Survival and prognostic factors among different types of
liposarcomas based on SEER database. Sci Rep. 15:17902025.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gootee JM, Curtin CE, Aurit SJ, Randhawa
SE, Kang BY and Silberstein PT: Treatment facility: An important
prognostic factor for dedifferentiated liposarcoma survival. Fed
Pract. 36 (Suppl 5):S34–S41. 2019.PubMed/NCBI
|
|
28
|
Fletcher C, Bridge J, Hogendoorn P and
Mertens F: WHO Classification of Tumours of Soft Tissue and Bone.
4th edition. IARC Press; 2013
|
|
29
|
Yang L, Chen S, Luo P, Yan W and Wang C:
Liposarcoma: Advances in cellular and molecular genetics
alterations and corresponding clinical treatment. J Cancer.
11:100–107. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moreau LC, Turcotte R, Ferguson P, Wunder
J, Clarkson P, Masri B, Isler M, Dion N, Werier J, Ghert M, et al:
Myxoid\round cell liposarcoma (MRCLS) revisited: An analysis of 418
primarily managed cases. Ann Surg Oncol. 19:1081–1088. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Haniball J, Sumathi VP, Kindblom LG, Abudu
A, Carter SR, Tillman RM, Jeys L, Spooner D, Peake D and Grimer RJ:
Prognostic factors and metastatic patterns in primary
myxoid/round-cell liposarcoma. Sarcoma. 2011:5380852011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chung PWM, Deheshi BM, Ferguson PC, Wunder
JS, Griffin AM, Catton CN, Bell RS, White LM, Kandel RA and
O'Sullivan B: Radiosensitivity translates into excellent local
control in extremity myxoid liposarcoma: A comparison with other
soft tissue sarcomas. Cancer. 115:3254–3261. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ho TP: Myxoid liposarcoma: How to stage
and follow. Curr Treat Options Oncol. 24:292–299. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Fiore M, Grosso F, Lo Vullo S,
Pennacchioli E, Stacchiotti S, Ferrari A, Collini P, Lozza L,
Mariani L, Casali PG and Gronchi A: Myxoid/round cell and
pleomorphic liposarcomas: Prognostic factors and survival in a
series of patients treated at a single institution. Cancer.
109:2522–2531. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Scapa JV, Cloutier JM, Raghavan SS,
Peters-Schulze G, Varma S and Charville GW: DDIT3
immunohistochemistry is a useful tool for the diagnosis of myxoid
liposarcoma. Am J Surg Pathol. 45:230–239. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Takazawa A, Yoshimura Y, Okamoto M, Tanaka
A, Kito M, Aoki K, Uehara T, Takahashi J, Kato H and Nakayama J:
The usefulness of immunohistochemistry for phosphohistone H3 as a
prognostic factor in myxoid liposarcoma. Sci Rep. 13:47332023.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Powers MP, Wang WL, Hernandez VS, Patel
KS, Lev DC, Lazar AJ and López-Terrada DH: Detection of myxoid
liposarcoma-associated FUS-DDIT3 rearrangement variants including a
newly identified breakpoint using an optimized RT-PCR assay. Mod
Pathol. 23:1307–1315. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Crozat A, Åman P, Mandahl N and Ron D:
Fusion of CHOP to a novel RNA-binding protein in human myxoid
liposarcoma. Nature. 363:640–644. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dal Cin P, Sciot R, Panagopoulos I, Aman
P, Samson I, Mandahl N, Mitelman F, Van den Berghe H and Fletcher
CD: Additional evidence of a variant translocation t(12;22) with
EWS/CHOP fusion in myxoid liposarcoma: Clinicopathological
features. J Pathol. 182:437–441. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Negri T, Virdis E, Brich S, Bozzi F,
Tamborini E, Tarantino E, Jocollè G, Cassinelli G, Grosso F,
Sanfilippo R, et al: Functional mapping of receptor tyrosine
kinases in myxoid liposarcoma. Clin Cancer Res. 16:3581–3593. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Trautmann M, Cyra M, Isfort I, Jeiler B,
Krüger A, Grünewald I, Steinestel K, Altvater B, Rossig C, Hafner
S, et al: Phosphatidylinositol-3-kinase (PI3K)/Akt signaling is
functionally essential in myxoid liposarcoma. Mol Cancer Ther.
18:834–844. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Trautmann M, Menzel J, Bertling C, Cyra M,
Isfort I, Steinestel K, Elges S, Grünewald I, Altvater B, Rossig C,
et al: FUS-DDIT3 fusion protein-driven IGF-IR signaling is a
therapeutic target in myxoid liposarcoma. Clin Cancer Res.
23:6227–6238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Demicco EG, Torres KE, Ghadimi MP, Colombo
C, Bolshakov S, Hoffman A, Peng T, Bovée JV, Wang WL, Lev D and
Lazar AJ: Involvement of the PI3K/Akt pathway in myxoid/round cell
liposarcoma. Mod Pathol. 25:212–221. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Koelsche C, Renner M, Hartmann W, Brandt
R, Lehner B, Waldburger N, Alldinger I, Schmitt T, Egerer G, Penzel
R, et al: TERT promoter hotspot mutations are recurrent in myxoid
liposarcomas but rare in other soft tissue sarcoma entities. J Exp
Clin Cancer Res. 33:332014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kunieda J, Yamashita K, Togashi Y, Baba S,
Sakata S, Inamura K, Ae K, Matsumoto S, Machinami R, Kitagawa M and
Takeuchi K: High prevalence of TERT aberrations in myxoid
liposarcoma: TERT reactivation may play a crucial role in
tumorigenesis. Cancer Sci. 113:1078–1089. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Tfayli Y, Baydoun A, Naja AS and Saghieh
S: Management of myxoid liposarcoma of the extremity. Oncol Lett.
22:5962021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dürr HR, Rauh J, Baur-Melnyk A, Knösel T,
Lindner L, Roeder F, Jansson V and Klein A: Myxoid liposarcoma:
Local relapse and metastatic pattern in 43 patients. BMC Cancer.
18:3042018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Zheng K, Yu XC, Xu M and Yang Y: Surgical
outcomes and prognostic factors of myxoid liposarcoma in
extremities: A retrospective study. Orthop Surg. 11:1020–1028.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Alaggio R, Coffin CM, Weiss SW, Bridge JA,
Issakov J, Oliveira AM and Folpe AL: Liposarcomas in young
patients: A study of 82 cases occurring in patients younger than 22
years of age. Am J Surg Pathol. 33:645–658. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Downes KA, Goldblum JR, Montgomery EA and
Fisher C: Pleomorphic liposarcoma: A clinicopathologic analysis of
19 cases. Mod Pathol. 14:179–184. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hornick JL, Bosenberg MW, Mentzel T,
McMenamin ME, Oliveira AM and Fletcher CDM: Pleomorphic
liposarcoma: Clinicopathologic analysis of 57 cases. Am J Surg
Pathol. 28:1257–1267. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Gardner JM, Dandekar M, Thomas D, Goldblum
JR, Weiss SW, Billings SD, Lucas DR, McHugh JB and Patel RM:
Cutaneous and subcutaneous pleomorphic liposarcoma: A
clinicopathologic study of 29 cases with evaluation of MDM2 gene
amplification in 26. Am J Surg Pathol. 36:1047–1051. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wang L, Luo R, Xiong Z, Xu J and Fang D:
Pleomorphic liposarcoma: An analysis of 6 case reports and
literature review. Medicine (Baltimore). 97:e99862018. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ghadimi MP, Liu P, Peng T, Bolshakov S,
Young ED, Torres KE, Colombo C, Hoffman A, Broccoli D, Hornick JL,
et al: Pleomorphic liposarcoma: Clinical observations and molecular
variables. Cancer. 117:5359–5369. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Conyers R, Young S and Thomas DM:
Liposarcoma: Molecular genetics and therapeutics. Sarcoma.
2011:4831542011. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Taylor BS, Barretina J, Socci ND,
Decarolis P, Ladanyi M, Meyerson M, Singer S and Sander C:
Functional copy-number alterations in cancer. PLoS One.
3:e31792008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Singer S, Socci ND, Ambrosini G, Sambol E,
Decarolis P, Wu Y, O'Connor R, Maki R, Viale A, Sander C, et al:
Gene expression profiling of liposarcoma identifies distinct
biological types/subtypes and potential therapeutic targets in
well-differentiated and dedifferentiated liposarcoma. Cancer Res.
67:6626–6636. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Wei S, Henderson-Jackson E, Qian X and Bui
MM: Soft tissue tumor immunohistochemistry update: Illustrative
examples of diagnostic pearls to avoid pitfalls. Arch Pathol Lab
Med. 141:1072–1091. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Oliveira AM and Nascimento AG: Pleomorphic
liposarcoma. Semin Diagn Pathol. 18:274–285. 2001.PubMed/NCBI
|
|
60
|
Anderson WJ and Jo VY: Pleomorphic
liposarcoma: Updates and current differential diagnosis. Semin
Diagn Pathol. 36:122–128. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Assi T, Ngo C, Faron M, Verret B, Lévy A,
Honoré C, Hénon C, Le Péchoux C, Bahleda R and Le Cesne A: Systemic
therapy in advanced pleomorphic liposarcoma: A comprehensive
review. Curr Treat Options Oncol. 24:1598–1613. 2023.PubMed/NCBI
|
|
62
|
Wan L, Tu C, Qi L and Li Z: Survivorship
and prognostic factors for pleomorphic liposarcoma: A
population-based study. J Orthop Surg Res. 16:1752021. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Eilber FC, Eilber FR, Eckardt J, Rosen G,
Riedel E, Maki RG, Brennan MF and Singer S: The impact of
chemotherapy on the survival of patients with high-grade primary
extremity liposarcoma. Ann Surg. 240:686–697. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Crago AM and Dickson MA: Liposarcoma:
Multimodality management and future targeted therapies. Surg Oncol
Clin N Am. 25:761–773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Ebey BN, Naouar S, Faidi B, Lahouar R, Ben
Khalifa B and El Kamel R: Pleomorphic spermatic cord liposarcoma: A
case report and review of management. Int J Surg Case Rep.
81:1057252021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Gebhard S, Coindre JM, Michels JJ, Terrier
P, Bertrand G, Trassard M, Taylor S, Château MC, Marquès B, Picot V
and Guillou L: Pleomorphic liposarcoma: Clinicopathologic,
immunohistochemical, and follow-up analysis of 63 cases: A study
from the French federation of cancer centers sarcoma group. Am J
Surg Pathol. 26:601–616. 2002. View Article : Google Scholar : PubMed/NCBI
|
